

Press Release

Martinsried/ Munich, Germany, February 22, 2021 – adivo GmbH entered into a partnership with a leading animal health company to develop therapeutic antibodies for companion animals. Under the terms of the collaboration agreement, the animal health company will have access to adivo's species-specific monoclonal antibody technology. Financial Terms were not disclosed.

PARTNERSHIP FOR THE DEVELOPMENT OF THERAPEUTIC ANTIBODIES FOR PETS

adivo entered into a global collaboration agreement with a leading animal health company

adivo has entered into a research and collaboration agreement with a leading animal health company to jointly discover and develop species-specific therapeutic monoclonal antibodies that address the current gap of effective therapies to sustainably treat severe conditions in dogs and cats.

Dr. Kathrin Ladetzki-Baehs, Founder and Managing Director of adivo said “our team is absolutely passionate on developing highly innovative therapeutics for pets to significantly improve the quality of lives for our four-legged companions as well as their respective owners. Today, we are excited to collaborate with such an experienced partner regarding development of therapeutic antibodies for pets, to further drive innovation in animal health.”

About adivo

adivo is a German biotech company based in Martinsried near Munich specializing in generating species-specific therapeutic antibodies for companion animals. The adivo team addresses high medical needs in pets including cancer and chronic inflammatory diseases. Using its proprietary phage display antibody libraries, adivo, either alone or with strategic partners, intends to generate therapeutics for companion animals that are well tolerated and highly efficacious as well. For further information, please refer to www.adivo.vet.

Contact

adivo

Dr. Kathrin Ladetzki-Baehs, phone +49 89 58 8088 471

Email: info@adivo.vet